GcMAF and Neurological Disorders
Supporting microglial activation and neuroinflammatory balance
Microglia are the resident macrophages of the central nervous system, responsible for immune surveillance, debris clearance, and maintaining neurological homeostasis. Research suggests that GcMAF may activate microglia, potentially supporting their protective functions in neuroinflammatory and neurodegenerative conditions including autism spectrum disorders, Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Key Findings
- GcMAF receptors identified on human microglia in peer-reviewed studies
- Research suggests potential improvements in social and cognitive markers in autism
- Studies indicate possible neuroprotective effects via reduced neuroinflammation
- Preliminary data supports exploration in Alzheimer's and dementia contexts
Mechanism of Action
GcMAF binds to specific receptors on microglia, stimulating their phagocytic capacity and cytokine modulation functions. This may help clear amyloid plaques, reduce neuroinflammation, and restore homeostatic signalling pathways disrupted in neurodegenerative disease.
Clinical Notes
Neurological applications of GcMAF are an active area of research. Clinical use should be supervised by a neurologist experienced in immunotherapy approaches.
Interested in GcMAF for Your Clinic?
Contact our medical team to discuss clinical applications and procurement.
Next Application
Autoimmune Diseases